Apotex - contamination   www.apotexterror.homestead.com         www.pharmaholocaust.com
I live like a walking death in twilight zone / some where in between death and a life being deprived of all Human Rights and Constitutional / Law 
protection by habitual offenders. I was assessed by three (3) independent psychiatrists to eliminate offender's speculations about my insanity 
prompting "delusions" etc. All psychiatrists stated clearly, that I am sane /I do NOT have/had any mental illness. No family history of any.
Apotex promoted products induced violence at work / antidepressant 

Dear Sir/Madam,

By not providing employees with any product info and personal protection 
Apotex promoted products induced violence at work / antidepressant 
nightmares. Withdrawal can often be more dangerous than continuing on a 
medication. It is important to withdraw extremely slowly from these drugs, 
usually over period of a year or more (conditions may not be reversible and 
may last a life time-often damage is permanent), under the supervision of a 
qualified specialist.
We did have on daily bases incidents/accidents and substantial product 
As all Operators and other Personnel I got massive exposure to unidentified 
product (s )- exposed to chemicals in processes.
Apotex, who exposes own employees to these extremely addictive drugs with 
out any protection, with no warning of the addictive properties should be 
held accountable for the results of that lack of warning and criminal 
Company terrorized by many means any one / other employees voicing concerns 
about issues with Safety, quality of the products and adverse side effects.
Employees worked with out any PPE/collective (Personal Protection Equipment) 
and sustained sever injuries on daily bases. Apotex subjected me to the most 
horrifying experiences imaginable. Withdrawal from these serotonergic 
antidepressants, according to the World Health Organization, appears to be 
even worse than the benzodiazaphines - which already have one of the worst 
reputations for serious withdrawal.
Company did not provide First Aid materials and employees had to supply 
themselves in "One dollar stores " with chip medical supply which on regular 
bases were ending up processed in the products.
AUTHORITIES HPFBI - Health Products and Food Branch Inspectorate.
Executives were reviewing Documents requested by HPFBI to reassure that they 
do not contain any info indicating non compliance with HPFBI 
investigation/regulations (fabrication of Documentation).
Company criminally concealed names/ nature of processed products. Company 
processed products with out regulatory permits in Facility not approved for 
those products (not providing any personal protection for Personnel), did 
not post Work Orders nor Safety Data Shits and did not disclose short and 
long term health hazards do to massive unprotected exposures . All Operators 
/Personnel displayed alarming level of problems with judgment/reasoning. 
They did have dramatically decreased concern for safety (obliviousness).
Routinely displayed signs of Dementia, aggression, radicalism etc.
. Always they appeared more capable than (s/he) actually were
. Operators reported no difficulty in doing certain tasks, yet they were 
unable to do them, or not be doing them.
. Due to massive and unprotected exposure to multitude of very potent 
/restricted active ingredients combined with lack of prior 
pharmaceutical/technical experience their specific skills deteriorated at 
different rates affecting different abilities. This resulted in them being 
able to do in limited manner some steps in a task but not others. Operator's 
denial of the decrease in abilities was common and in results dangerous).
I am dying every day in excruciating pains.
The type/variety of my pains are countless and in manifestation horrifying.
I have cluster of symptoms, and there is no definitive cure. This is 
tremendously frustrating to physicians and that means, I AS A PATIENT DO 
Apotex (with accomplices) denied me medical help, deprived me of all means 
of sustaining myself and is not regretful. Imposed on me poverty, immense 
stress and obstacles etc.
Those issues amongst other were neglected:
The holder of an establishment licence, or any operation to which the 
requirements of Division 2 are applicable, must ensure that the fabrication, 
packaging, labelling, distribution, testing, and wholesaling of drugs comply 
with the requirements of the marketing authorization and do not place 
consumers at risk due to inadequate safety and quality. The attainment of 
this quality objective is the responsibility of senior management and 
requires the participation and commitment of personnel in many different 
departments and at all levels within the establishment and its suppliers. To 
achieve the objective reliably, there must be a comprehensively designed and 
correctly implemented system of quality assurance that incorporates Good 
Manufacturing Practices and thus quality control. The system should be 
fullydocumented and its effectiveness monitored. All parts of the quality 
assurance systems should be adequately resourced with qualified personnel, 
suitable premises, equipment, and facilities. There are additional 
legislative responsibilities for the holder of the establishment licence
and for the person(s) authorized to market drug products.
The basic concepts of quality assurance, Good Manufacturing Practices and 
quality control are interrelated.
They are described here in order to emphasize their relationships and their 
importance to the production and control of drugs.
Quality assurance is a wide-ranging concept that covers all matters that 
individually or collectively influence the quality of a drug. It is the 
total of the organized arrangements made with the objective of ensuring that 
drugs are of the quality required for their intended use. Quality assurance 
therefore incorporates Good Manufacturing Practices, along with other 
factors that are outside the scope of these guidelines.
A system of quality assurance appropriate for the manufacture of drugs 
should ensure that:
1. Drugs are designed and developed in a way that takes into account the GMP 
2. Managerial responsibilities are clearly specified;
3. Systems, facilities and procedures are adequate;
4. Production and control operations are clearly specified, and GMP are 
5. Arrangements are made for the supply and use of the correct raw and 
packaging materials;
6. Control on intermediates, in-process monitoring, and validation 
activities are carried out;
7. The finished product is processed, packaged/labelled, verified, and 
tested according to
defined procedures;
8. Drugs are not sold or supplied before the quality control department has 
indicated that each batch has been produced and controlled in accordance 
with the requirements of the marketing authorization and of any other 
regulations relevant to the production, control and release of drugs;
9. Satisfactory arrangements exist for ensuring that the drugs are stored, 
distributed, and
subsequently handled in such a way that quality is maintained throughout 
their shelf life;
10. There is a procedure for self-inspection and/or quality audit that 
regularly appraises the effectiveness and applicability of the quality 
assurance system;
Good Manufacturing Practices (GMP) are the part of quality assurance that 
ensures that drugs are consistently produced and controlled in such a way to 
meet the quality standards appropriate to their intended use, as required by 
the marketing authorization.
GMP are concerned with both production and quality control. Their basic 
requirements are as follows:
1. Manufacturing processes are clearly defined and controlled. All critical 
processes are
validated to ensure consistency and compliance with specifications.
2. Manufacturing processes are controlled, and any changes to the process 
are evaluated.
Changes that have an impact on the quality of the drug are validated as 
3. All necessary key elements for GMP are provided, including the following:
- qualified and trained personnel
- adequate premises and space
- suitable equipment and services
- correct materials, containers and labels
- approved procedures and instructions
- suitable storage and transport
4. Instructions and procedures are written in clear and unambiguous 
5. Operators are trained to carry out and document procedures;
6. Records are made, manually or by instruments, during manufacture that 
demonstrate that all the steps required by the defined procedures and 
instructions were in fact taken and that the quantity and quality of the 
drug was as expected. Deviations are investigated and documented;
7. Records of manufacture (including distribution) that enable the complete 
history of a batch to be traced are retained in a comprehensible and 
accessible form;
8. The distribution of the drugs minimizes any risk to their quality;
9. A system is available for recalling any batch of drug from sale or 
10. Complaints about marketed drugs are examined, the causes of quality 
defects are
investigated, and appropriate measures are taken with respect to the 
defective drugs and to prevent recurrence.
Quality control is the part of GMP that is concerned with sampling, 
specifications, testing, documentation and release procedures. This approach 
ensures that materials are not released for use, and that drugs released for 
sale or supply, until their quality has been deemed satisfactory.
The basic requirements of quality control are as follows:
1. Adequate facilities, trained personnel, and approved procedures are 
available for sampling, inspecting and testing of raw materials, packaging 
materials, intermediate bulk and finished products, and, where appropriate 
monitoring environmental conditions for GMP purposes;
1.1 Samples of raw materials, packaging materials, and intermediate, bulk, 
and finished
products are taken according to procedures approved by the quality control
1.2 Test methods are validated;
1.3 Records are made that demonstrate that all the required sampling, 
inspecting, and
testing procedures were actually carried out, and any deviations are 
recorded and
1.4 The finished products contain active ingredients that comply with the 
qualitative and
quantitative composition requirements of the marketing authorization, have 
the purity
required, are enclosed within their proper container and are correctly 
1.5 Records are made of the results of inspection, and to show that testing 
of materials,
and of intermediate, bulk, and finished products is formally assessed 
1.6 Product assessment includes a review and evaluation of relevant 
documentation and an assessment of deviations from specified procedures;
1.7 No batch of drug is released for sale or supply prior to approval by the 
quality control
department, in accordance with the requirements of the marketing 
(Notice of Compliance (NOC), Drug Identification Number (DIN));
1.8 Sufficient reference samples of raw materials and drugs are retained to 
permit future
examination of the drug if necessary, and the drug is retained in its final 
pack unless
exceptionally large packs are produced.
ACTIVE PHARMACEUTICAL INGREDIENT(ingrédient pharmaceutique actif) - Any 
substance or mixture of substances that is intended to be used in the 
manufacture of a drug (medicinal) product and that, when used in the 
production of a drug, becomes an active ingredient of the drug product. Such 
substances are intended to furnish pharmacological activity or other direct 
effect in the diagnosis, cure, mitigation, treatment, or prevention of 
disease or to affect the structure and function of the body. (ICH, Q7A, step 
BATCH (lot de fabrication) - A quantity of drug in dosage form, a raw 
material, or a
packaging material, homogeneous within specified limits, produced according 
to a single production order and as attested by the signatories to the 
order. In the case of continuous manufacture, a batch corresponds to a 
defined fraction of the production, that is characterized by its intended 
homogeneity. It may sometimes be necessary to divide a batch into a number 
of sub-batches, which are later brought together to form a final homogeneous 
BATCH CERTIFICATE (certificat de lot) - A certificate issued by the 
fabricator of a lot or batch of a drug that is exported within the framework 
of a mutual recognition agreement and in which the fabricator
(a) identifies the master production document for the drug and certifies 
that the lot or batch has been fabricated, packaged/labelled and tested in 
with the procedures described in that document;
(b) provides a detailed description of the drug, including
(i) a statement of all properties and qualities of the drug, including the
identity, potency and purity of the drug, and
(ii) a statement of tolerances for the properties and qualities of the drug;
(C) identifies the analytical methods used in testing the lot or batch and 
details of the analytical results obtained;
(d) sets out the addresses of the buildings at which the lot or batch was
fabricated, packaged/labelled and tested; and
(e) certifies that the lot or batch was fabricated, packaged/labelled and 
in accordance with the good manufacturing practices of the regulatory
authority that has recognized those buildings as meeting its good
manufacturing practices standard. (C.01A.001)
BATCH NUMBER (numéro de lot de fabrication) - A distinctive combination of 
and/or letters that specifically identifies a batch. The batch number 
appears on the batch
records, certificates of analysis, etc.
BRACKETING (méthode des extrêmes) - The design of a stability schedule such 
that only samples on the extremes of certain design factors (e.g., strength, 
package size) are tested at all time points as in a full design. The design 
assumes that the stability of any intermediate levels is represented by the 
stability of the extremes tested. Where a range of strengths is to be 
tested, bracketing is applicable if the strengths are identical or very 
closely related in composition (e.g., for a tablet range made with different 
compression weights of a similar basic granulation, or a capsule range made 
by filling different plug fill weights of the same basic composition into 
different sized capsule shells). Bracketing can be applied to different 
container sizes or to different fills in the same container closure system. 
(ICH, Q1A(R))
BULKDRUG(drogue en vrac) - Unpackaged dosage form, usually in quantities 
larger than the largest commercially available package size.
CERTIFICATE OFMANUFACTURE(certificat de fabrication) - A document issued by 
a vendor to a distributor or importer that attests that a specific lot or 
batch of drug has been produced in accordance with its master production 
document. Such certificates include a detailed summary of current batch 
documentation, with reference to respective dates of revision, manufacture, 
and packaging, and are signed and dated by the vendor's quality control 
CHANGE CONTROL(contrôle des changements) -Awritten procedure that describes 
the action to be taken if a change is proposed (a) to facilities, materials, 
equipment, and/or processes used in the fabrication, packaging, and testing 
of drugs, or (b) that may affect the operation of the quality or support 
CHANGE OVERPROCEDURE (procédure de conversion) - A logical series of 
validated steps that ensures the proper cleaning of suites and equipment 
before the processing of a different product begins.
CLEAN AREA(aire propre) -Aroom or suite of rooms where GradeC orDconditions 
table in Section C.02.029 of these guidelines) are required. The rooms have 
a defined
environmental control of particulate and microbial contamination and are 
maintained, and used in such a wayas to minimize the introduction, 
generation, and retention of contaminants.
CRITICAL PROCESS (procédé critique) - A process that may cause significant 
variation in the quality of the finished product.
DATE OF FABRICATION (date de fabrication) - Unless otherwise defined in the 
and Drug Regulations, this is the date when any active ingredient, 
anti-oxidant, preservative,
or air/oxygen scavenger is first added to the lot being processed.
"Yet who Knows the Truth and Calls it a Lie, is a Criminal."
Well, I have to give to Apotex a credit for flexibility and adaptability.
I ADMIRED CEO Dr. Bernard Sherman and Jack Kay, President & COO of Apotex 
Recently again Apotex was ravaged /compromised by scandals of notorious 
contamination / non compliance and now it does what they do the best- do 
what ever it takes to bit the system and by strategic move reviews portfolio 
of 300 products.
Scandals with routine quality /contamination issues of large number of own 
label products, APOTEX overcomes with a brilliant strategic move. Now will 
cash on sale of more than 40 pharmaceutical products to AA Pharma and will 
continue to do the production of these products in Facilities 
blamed/notorious for contamination / non compliance.
These products represent important / different therapeutic categories and 
the sale takes effect as of August 3rd, 2010.
AA Pharma will immediately start selling these products and the Apotex label 
will be transitioned to the new name over a period of time so the 
Authorities and CUSTOMERS will be led to think, that they are using new 
/safe products.
Personally as a former employee of this organization I wish Apotex all 
success in recovery process and hope that Apotex can have corporate dignity 
to step up to its obligations and compensate its "victims" for corporate 

Apotex's victim